| Dr Kristine Badin, MD | |
|
1947 John F Kennedy Blvd, Jersey City, NJ 07305 | |
| (908) 922-1704 | |
| (201) 360-0159 |
| Full Name | Dr Kristine Badin |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 1947 John F Kennedy Blvd, Jersey City, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417364456 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 25MA10752300 (New Jersey) | Primary |
| Entity Name | Michel S Badin Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871137471 PECOS PAC ID: 3476985326 Enrollment ID: O20191114000178 |
News Archive
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.
Important insights that explain why our ability to ward off infection declines with age are published in a new research report in the July 2012 issue of the Genetics Society of America's journal, GENETICS.
Researchers at the Federal University of Rio Grande do Sul, the university hospital (Hospital de Cl-nicas de Porto Alegre, HCPA) and the Children's Cancer Institute (Instituto do C-ncer Infantil do Rio Grande do Sul, ICI-RS) in Porto Alegre, Brazil, have shown that manipulating an epigenetic mechanism, which regulates gene expression, may promote cell death and favor maturation towards less malignant-prone phenotypes in pediatric brain cancer cell lines.
A new strategy that researchers believe provides a more comprehensive screening of the entire chromosomal makeup of an embryo shows tremendous promise in the field of preimplantation genetic screening (PGS) according to a study published in the December issue of Fertility and Sterility.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kristine Badin, MD 1947 John F Kennedy Blvd, Jersey City, NJ 07305 Ph: (908) 922-1704 | Dr Kristine Badin, MD 1947 John F Kennedy Blvd, Jersey City, NJ 07305 Ph: (908) 922-1704 |
News Archive
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.
Important insights that explain why our ability to ward off infection declines with age are published in a new research report in the July 2012 issue of the Genetics Society of America's journal, GENETICS.
Researchers at the Federal University of Rio Grande do Sul, the university hospital (Hospital de Cl-nicas de Porto Alegre, HCPA) and the Children's Cancer Institute (Instituto do C-ncer Infantil do Rio Grande do Sul, ICI-RS) in Porto Alegre, Brazil, have shown that manipulating an epigenetic mechanism, which regulates gene expression, may promote cell death and favor maturation towards less malignant-prone phenotypes in pediatric brain cancer cell lines.
A new strategy that researchers believe provides a more comprehensive screening of the entire chromosomal makeup of an embryo shows tremendous promise in the field of preimplantation genetic screening (PGS) according to a study published in the December issue of Fertility and Sterility.
› Verified 4 days ago
Dr. Alita Logrono Dizon, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 377 Jersey Ave, Suite 460, Jersey City, NJ 07302 Phone: 201-332-4110 Fax: 201-332-4122 | |
Mrs. Sonia Castaneda Velasco, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 172 Newark Ave, Jersey City, NJ 07302 Phone: 201-332-4727 Fax: 201-332-4157 | |
Dr. Vladimir Znamensky, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 120 Franklin St, Jersey City, NJ 07307 Phone: 201-216-9791 Fax: 201-216-1362 | |
Saira Shah, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 355 Grand St, Medicine Dept,3rd Floor, Jersey City, NJ 07302 Phone: 201-915-2000 | |
Zorayda Olaya De Leon, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 311 Palisade Ave, Jersey City, NJ 07307 Phone: 201-963-5500 Fax: 201-963-5563 | |
Dr. Jared Saul Krok, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 355 Grand St, Jersey City, NJ 07302 Phone: 201-915-2431 | |
Merwin F Richard, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 550 Newark Ave, Ste 307, Jersey City, NJ 07306 Phone: 201-418-9111 Fax: 201-418-9118 |